Top Markets
#1 Black Phoenix Black Phoenix +167.57%
#2 Islamic Coin Islamic Coin +158.27%
#3 Glidr Glidr +84.34%
#4 Acurast Acurast +33.17%
#5 Test Test +21.48%
#6 Cryptopia Cryptopia +20.92%
#7 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +18.26%
#8 Quantum Resistant Ledger Quantum Resistant Ledger +16.56%
#9 stake.link stake.link +9.38%
#10 Wrapped Bitcoin (PulseChain) Wrapped Bitcoin (PulseChain) +9.37%
Coin of the day
Black Phoenix Black Phoenix
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
Q BioMed Inc. Q BioMed Inc.

Q BioMed Inc.

QBIO
Classifica tra le azioni #41615
Q BioMed Inc. functions as a biomedical accelerator and developer, actively... Q BioMed Inc. functions as a biomedical accelerator and developer, actively licensing, acquiring, and supplying resources to firms within the life sciences and healthcare sectors. Its commercial portfolio includes Metastron (Strontium Chloride SR89), a radiopharmaceutical designed to alleviate pain associated with metastatic bone cancer. Additionally, Q BioMed is advancing a pipeline of therapeutic candidates, including Man-01, a pre-clinical compound aimed at primary open-angle glaucoma; QBM-001, intended for rare pediatric non-verbal autism spectrum disorder; and Uttroside-B, which targets liver cancer. The company also collaborates with Mannin Research Inc. on the development of treatments for conditions such as acute respiratory distress syndrome, glaucoma, and various kidney diseases. Incorporated in New York, New York, in 2013, the entity was initially named ISMO Tech Solutions, Inc. before adopting its current name, Q BioMed Inc., in July 2015.
Prezzo delle azioni
$0.0001
Ultima sincronizzazione: 2026-04-02
Capitalizzazione di mercato
$14.51K
Variazione (1 giorno)
0.00%
Variazione (1 anno)
9,900.00%
Paese
US
Scambia Q BioMed Inc. (QBIO)

Categoria

Healthcare
Rapporto P/S per Q BioMed Inc. (QBIO)
Rapporto P/S al 2026 TTM: 0
Secondo gli ultimi rapporti finanziari e il prezzo delle azioni di Q BioMed Inc., il rapporto P/S attuale (TTM) è 0. Alla fine del 2026, era pari a 0.
Storico del rapporto P/S per Q BioMed Inc. da 2026 a 2026
Rapporto P/S alla fine di ogni anno
Anno Rapporto P/S Cambia
Non abbastanza dati per le date fornite.
Rapporto P/S per aziende simili o concorrenti
Azienda Rapporto P/S Differenza del rapporto P/S Il paese
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
9.88 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
10.30 -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
4.98 -
BE
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR